The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer

R. D. Rossen, M. A. Reisberg, Evan M Hersh, J. U. Gutterman

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Sera from 134 selected patients with various types of cancer were tested for soluble antigen antibody complexes by the C1q binding method. Sera from 85 healthy blood bank donors served as normal controls. C1q binding activity (C1q BA) values above the 95th percentile for healthy subjects were found in 83% of sera from patients with neoplastic diseases. The incidence of abnormal C1q BA values among patients with malignant melanoma was 83%, with breast cancer 74%, with colon cancer 75%, with lung cancer 88%, with leukemia and lymphoma 85%, and with miscellaneous tumors 94%. High C1q BA values were found most frequently in sera of patients who had been diagnosed relatively recently (within 5 mth) and who had evident residual disease after surgical treatment. Recurrence or progression of tumor growth occurred significantly more frequently in lung cancer patients with high C1q BA. DNA was not detected in cancer patients' sera and treatment with DNase did not decrease in C1q BA. C1q BA in sera could not be explained by the presence of antiglobulin antibodies. Sucrose density gradient ultracentrifugation studies of the serum C1q BA in 4 cancer patients showed that the major binding activity was found between 19S and 7S.

Original languageEnglish (US)
Pages (from-to)1205-1215
Number of pages11
JournalJournal of the National Cancer Institute
Volume58
Issue number5
StatePublished - 1977
Externally publishedYes

Fingerprint

Antigen-Antibody Complex
Serum
Neoplasms
Lung Neoplasms
Blood Banks
Deoxyribonucleases
Ultracentrifugation
Blood Donors
Colonic Neoplasms
Sucrose
Anti-Idiotypic Antibodies
Melanoma
Lymphoma
Healthy Volunteers
Leukemia
Breast Neoplasms
Recurrence
Antibodies
DNA
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The C1q binding test for soluble immune complexes : clinical correlations obtained in patients with cancer. / Rossen, R. D.; Reisberg, M. A.; Hersh, Evan M; Gutterman, J. U.

In: Journal of the National Cancer Institute, Vol. 58, No. 5, 1977, p. 1205-1215.

Research output: Contribution to journalArticle

@article{d52147cdda1944a983f8ac5484ca1e54,
title = "The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer",
abstract = "Sera from 134 selected patients with various types of cancer were tested for soluble antigen antibody complexes by the C1q binding method. Sera from 85 healthy blood bank donors served as normal controls. C1q binding activity (C1q BA) values above the 95th percentile for healthy subjects were found in 83{\%} of sera from patients with neoplastic diseases. The incidence of abnormal C1q BA values among patients with malignant melanoma was 83{\%}, with breast cancer 74{\%}, with colon cancer 75{\%}, with lung cancer 88{\%}, with leukemia and lymphoma 85{\%}, and with miscellaneous tumors 94{\%}. High C1q BA values were found most frequently in sera of patients who had been diagnosed relatively recently (within 5 mth) and who had evident residual disease after surgical treatment. Recurrence or progression of tumor growth occurred significantly more frequently in lung cancer patients with high C1q BA. DNA was not detected in cancer patients' sera and treatment with DNase did not decrease in C1q BA. C1q BA in sera could not be explained by the presence of antiglobulin antibodies. Sucrose density gradient ultracentrifugation studies of the serum C1q BA in 4 cancer patients showed that the major binding activity was found between 19S and 7S.",
author = "Rossen, {R. D.} and Reisberg, {M. A.} and Hersh, {Evan M} and Gutterman, {J. U.}",
year = "1977",
language = "English (US)",
volume = "58",
pages = "1205--1215",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - The C1q binding test for soluble immune complexes

T2 - clinical correlations obtained in patients with cancer

AU - Rossen, R. D.

AU - Reisberg, M. A.

AU - Hersh, Evan M

AU - Gutterman, J. U.

PY - 1977

Y1 - 1977

N2 - Sera from 134 selected patients with various types of cancer were tested for soluble antigen antibody complexes by the C1q binding method. Sera from 85 healthy blood bank donors served as normal controls. C1q binding activity (C1q BA) values above the 95th percentile for healthy subjects were found in 83% of sera from patients with neoplastic diseases. The incidence of abnormal C1q BA values among patients with malignant melanoma was 83%, with breast cancer 74%, with colon cancer 75%, with lung cancer 88%, with leukemia and lymphoma 85%, and with miscellaneous tumors 94%. High C1q BA values were found most frequently in sera of patients who had been diagnosed relatively recently (within 5 mth) and who had evident residual disease after surgical treatment. Recurrence or progression of tumor growth occurred significantly more frequently in lung cancer patients with high C1q BA. DNA was not detected in cancer patients' sera and treatment with DNase did not decrease in C1q BA. C1q BA in sera could not be explained by the presence of antiglobulin antibodies. Sucrose density gradient ultracentrifugation studies of the serum C1q BA in 4 cancer patients showed that the major binding activity was found between 19S and 7S.

AB - Sera from 134 selected patients with various types of cancer were tested for soluble antigen antibody complexes by the C1q binding method. Sera from 85 healthy blood bank donors served as normal controls. C1q binding activity (C1q BA) values above the 95th percentile for healthy subjects were found in 83% of sera from patients with neoplastic diseases. The incidence of abnormal C1q BA values among patients with malignant melanoma was 83%, with breast cancer 74%, with colon cancer 75%, with lung cancer 88%, with leukemia and lymphoma 85%, and with miscellaneous tumors 94%. High C1q BA values were found most frequently in sera of patients who had been diagnosed relatively recently (within 5 mth) and who had evident residual disease after surgical treatment. Recurrence or progression of tumor growth occurred significantly more frequently in lung cancer patients with high C1q BA. DNA was not detected in cancer patients' sera and treatment with DNase did not decrease in C1q BA. C1q BA in sera could not be explained by the presence of antiglobulin antibodies. Sucrose density gradient ultracentrifugation studies of the serum C1q BA in 4 cancer patients showed that the major binding activity was found between 19S and 7S.

UR - http://www.scopus.com/inward/record.url?scp=0017399149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017399149&partnerID=8YFLogxK

M3 - Article

C2 - 323505

AN - SCOPUS:0017399149

VL - 58

SP - 1205

EP - 1215

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -